BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, July 10, 2025
Home » Topics » License, BioWorld Science

License, BioWorld Science
License, BioWorld Science RSS Feed RSS

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow
Immune

Otsuka licenses Harbour Biomed’s BCMAxCD3 bispecific T-cell engager HBM-7020

June 23, 2025
No Comments
Harbour Biomed Ltd. has established a global strategic collaboration with Otsuka Pharmaceutical Co. Ltd. to advance BCMAxCD3 bispecific T-cell engagers for the treatment of autoimmune diseases.
Read More
Test tubes, dropper
Respiratory

Transpire Bio licenses rights to Intragrand’s PDE4 inhibitor ITG-1052

June 4, 2025
No Comments
Transpire Bio Inc. has signed an exclusive license agreement with Suzhou Intragrand Pharma Co. Ltd. for ITG-1052 (lenamilast), an investigational phosphodiesterase 4 (PDE4) inhibitor.
Read More
Scientists shaking hands in the lab
Inflammatory

Sanofi exercises option to license STAT6 program from Nurix collaboration

June 3, 2025
No Comments
Sanofi SA has exercised its option to exclusively license Nurix Therapeutics Inc.’s STAT6 program, including the drug development candidate NX-3911, an oral, highly selective STAT6 degrader.
Read More
Illustration of human brain and dna
Neurology/psychiatric

Quralis signs agreements to further fragile X syndrome research

May 16, 2025
No Comments
Quralis Corp. has entered into a number of agreements with the aim of advancing the treatment of fragile X syndrome, a genetic condition caused by a mutation of a single gene – fragile X messenger ribonucleoprotein 1 (FMR1) – on the X chromosome.
Read More
Antibody-drug conjugate
Immuno-oncology

Formosa and Almac Discovery sign license agreement for EGFRxROR1 bispecific ADC

May 7, 2025
No Comments
Formosa Pharmaceuticals Inc. and Almac Discovery Ltd. have announced a global licensing agreement for development and commercialization of ALM-401, a first-in-class engineered bispecific antibody-drug conjugate (ADC) for the treatment of solid tumors characterized by the dual expression of EGFR and ROR1.
Read More
Conceptual 3D illustration showing degradation of motor neuron
Neurology/psychiatric

Alchemab and Lilly sign licensing agreement for ATLX-1282

May 6, 2025
No Comments
Alchemab Therapeutics Ltd. has entered into a licensing agreement with Eli Lilly and Co. for ATLX-1282, Alchemab’s first-in-class IND-ready program targeting a novel receptor and mechanism for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.
Read More
Illustration of lymphocytes
Immune

Boehringer Ingelheim and Cue Biopharma agree to advance CUE-501 for autoimmune diseases

April 15, 2025
Boehringer Ingelheim Pharma GmbH & Co KG and Cue Biopharma Inc. have signed a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501, a differentiated B-cell depletion therapy for autoimmune diseases.
Read More
Neurology/psychiatric

Lilly licenses rights to use Sangamo’s neurotropic AAV capsid in genomic medicines

April 4, 2025
Sangamo Therapeutics Inc. has entered into a license agreement with Eli Lilly and Co., allowing Lilly to use Sangamo’s novel proprietary neurotropic AAV capsid, STAC-BBB, to deliver intravenously administered genomic medicines to treat certain diseases of the central nervous system.
Read More
Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow
Immuno-oncology

Sotio exercises option to license Synaffix technology for ADC programs

March 14, 2025
Sotio Biotech AS is exercising an option under a license and option agreement to obtain a license to Synaffix BV’s technology to develop two bispecific antibody-drug conjugate (ADC) programs  for solid tumors.
Read More
Skin exam
Immune

Photys licenses rights to Polymed’s IRAK-4 degrader

Feb. 21, 2025
Photys Therapeutics Inc. has signed a license agreement with Hangzhou Polymed Biopharmaceuticals Inc. for HPB-143, a phase I-ready IRAK-4 degrader. IRAK-4 degradation offers potential to treat various autoimmune indications, including atopic dermatitis and hidradenitis suppurativa.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 13 14 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 10, 2025.
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing